BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 19906496)

  • 1. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
    Jansen JF; Schöder H; Lee NY; Wang Y; Pfister DG; Fury MG; Stambuk HE; Humm JL; Koutcher JA; Shukla-Dave A
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1403-10. PubMed ID: 19906496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
    Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of metastatic lymph nodes in head and neck squamous cell carcinomas using simultaneous
    Chen J; Hagiwara M; Givi B; Schmidt B; Liu C; Chen Q; Logan J; Mikheev A; Rusinek H; Kim SG
    Sci Rep; 2020 Nov; 10(1):20764. PubMed ID: 33247166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
    Simoncic U; Leibfarth S; Welz S; Schwenzer N; Schmidt H; Reischl G; Pfannenberg C; Fougère C; Nikolaou K; Zips D; Thorwarth D
    Med Phys; 2017 Jun; 44(6):2358-2368. PubMed ID: 28317128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
    Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
    Nehmeh SA; Lee NY; Schröder H; Squire O; Zanzonico PB; Erdi YE; Greco C; Mageras G; Pham HS; Larson SM; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):235-42. PubMed ID: 18086391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric Imaging of Tumor Hypoxia and Perfusion with
    Grkovski M; Schöder H; Lee NY; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
    J Nucl Med; 2017 Jul; 58(7):1072-1080. PubMed ID: 28183993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
    Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
    Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal
    Gertsenshteyn I; Epel B; Ahluwalia A; Kim H; Fan X; Barth E; Zamora M; Markiewicz E; Tsai HM; Sundramoorthy S; Leoni L; Lukens J; Bhuiyan M; Freifelder R; Kucharski A; Giurcanu M; Roman BB; Karczmar G; Kao CM; Halpern H; Chen CT
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4014-4024. PubMed ID: 35792927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
    Gagel B; Reinartz P; Dimartino E; Zimny M; Pinkawa M; Maneschi P; Stanzel S; Hamacher K; Coenen HH; Westhofen M; Büll U; Eble MJ
    Strahlenther Onkol; 2004 Oct; 180(10):616-22. PubMed ID: 15480509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.
    Cho H; Ackerstaff E; Carlin S; Lupu ME; Wang Y; Rizwan A; O'Donoghue J; Ling CC; Humm JL; Zanzonico PB; Koutcher JA
    Neoplasia; 2009 Mar; 11(3):247-59, 2p following 259. PubMed ID: 19242606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
    Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
    Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.
    Rajendran JG; Schwartz DL; O'Sullivan J; Peterson LM; Ng P; Scharnhorst J; Grierson JR; Krohn KA
    Clin Cancer Res; 2006 Sep; 12(18):5435-41. PubMed ID: 17000677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma.
    Yamane T; Kikuchi M; Shinohara S; Senda M
    Mol Imaging Biol; 2011 Apr; 13(2):227-31. PubMed ID: 20552284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
    Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
    J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
    Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
    F1000Res; 2020; 9():1350. PubMed ID: 33796277
    [No Abstract]   [Full Text] [Related]  

  • 18. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
    Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
    Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study.
    Pinker K; Andrzejewski P; Baltzer P; Polanec SH; Sturdza A; Georg D; Helbich TH; Karanikas G; Grimm C; Polterauer S; Poetter R; Wadsak W; Mitterhauser M; Georg P
    PLoS One; 2016; 11(5):e0155333. PubMed ID: 27167829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.